Treatment of anthracycline-resistant breast cancer

Research output: Contribution to journalArticle

Abstract

The anthracyclines are commonly used for the treatment of early stage and advanced stage breast cancer, but many patients develop resistance to therapy. The definition of anthracycline resistance varies considerably in the literature, but in most cases includes disease progression during or within 6-12 months after completion of anthracycline therapy. Some authors have distinguished true anthracycline resistance (defined as progression during anthracycline therapy) from anthracycline pretreatment (defined as progression after completion of therapy). Single agents that have demonstrated response rates of at least 15-20% in anthracycline pretreated or resistant disease include the antitubulin agents (docetaxel, paclitaxel, vinorelbine), antimetabolites (capecitabine, fluorouracil), nucleoside analogues (gemcitabine), and trastuzumab (for HER2/neu positive disease only). Phase III studies have demonstrated that docetaxel is more effective than paclitaxel, mitomycin/vinblastine, and methotrexate/fluorouracil, and that the docetaxel/capecitabine combination is more effective than docetaxel alone. The decision regarding which agent(s) to use should be based upon the patient's prior treatment history, tumor biology (HER2/neu and hormone receptor expression), comorbid conditions (e.g. neuropathy, heart disease), and other considerations (e.g. insurance coverage for oral medication). The choice of a specific treatment regimen must be individualized based upon these considerations.

Original languageEnglish (US)
Pages (from-to)151-162
Number of pages12
JournalAmerican Journal of Cancer
Volume3
Issue number3
DOIs
StatePublished - 2004

Fingerprint

docetaxel
Anthracyclines
Breast Neoplasms
gemcitabine
Paclitaxel
Fluorouracil
Therapeutics
ErbB-2 Receptor
Antimetabolites
Insurance Coverage
Vinblastine
Mitomycin
Nucleosides
Methotrexate
Disease Progression
Heart Diseases
History
Hormones

ASJC Scopus subject areas

  • Oncology

Cite this

Treatment of anthracycline-resistant breast cancer. / Friedman, Daniel T.; Sparano, Joseph A.

In: American Journal of Cancer, Vol. 3, No. 3, 2004, p. 151-162.

Research output: Contribution to journalArticle

@article{2f366f6f8c874ebb8f1d2201be96ad13,
title = "Treatment of anthracycline-resistant breast cancer",
abstract = "The anthracyclines are commonly used for the treatment of early stage and advanced stage breast cancer, but many patients develop resistance to therapy. The definition of anthracycline resistance varies considerably in the literature, but in most cases includes disease progression during or within 6-12 months after completion of anthracycline therapy. Some authors have distinguished true anthracycline resistance (defined as progression during anthracycline therapy) from anthracycline pretreatment (defined as progression after completion of therapy). Single agents that have demonstrated response rates of at least 15-20{\%} in anthracycline pretreated or resistant disease include the antitubulin agents (docetaxel, paclitaxel, vinorelbine), antimetabolites (capecitabine, fluorouracil), nucleoside analogues (gemcitabine), and trastuzumab (for HER2/neu positive disease only). Phase III studies have demonstrated that docetaxel is more effective than paclitaxel, mitomycin/vinblastine, and methotrexate/fluorouracil, and that the docetaxel/capecitabine combination is more effective than docetaxel alone. The decision regarding which agent(s) to use should be based upon the patient's prior treatment history, tumor biology (HER2/neu and hormone receptor expression), comorbid conditions (e.g. neuropathy, heart disease), and other considerations (e.g. insurance coverage for oral medication). The choice of a specific treatment regimen must be individualized based upon these considerations.",
author = "Friedman, {Daniel T.} and Sparano, {Joseph A.}",
year = "2004",
doi = "10.2165/00024669-200403030-00002",
language = "English (US)",
volume = "3",
pages = "151--162",
journal = "American Journal of Cancer",
issn = "1175-6357",
publisher = "Adis International Ltd",
number = "3",

}

TY - JOUR

T1 - Treatment of anthracycline-resistant breast cancer

AU - Friedman, Daniel T.

AU - Sparano, Joseph A.

PY - 2004

Y1 - 2004

N2 - The anthracyclines are commonly used for the treatment of early stage and advanced stage breast cancer, but many patients develop resistance to therapy. The definition of anthracycline resistance varies considerably in the literature, but in most cases includes disease progression during or within 6-12 months after completion of anthracycline therapy. Some authors have distinguished true anthracycline resistance (defined as progression during anthracycline therapy) from anthracycline pretreatment (defined as progression after completion of therapy). Single agents that have demonstrated response rates of at least 15-20% in anthracycline pretreated or resistant disease include the antitubulin agents (docetaxel, paclitaxel, vinorelbine), antimetabolites (capecitabine, fluorouracil), nucleoside analogues (gemcitabine), and trastuzumab (for HER2/neu positive disease only). Phase III studies have demonstrated that docetaxel is more effective than paclitaxel, mitomycin/vinblastine, and methotrexate/fluorouracil, and that the docetaxel/capecitabine combination is more effective than docetaxel alone. The decision regarding which agent(s) to use should be based upon the patient's prior treatment history, tumor biology (HER2/neu and hormone receptor expression), comorbid conditions (e.g. neuropathy, heart disease), and other considerations (e.g. insurance coverage for oral medication). The choice of a specific treatment regimen must be individualized based upon these considerations.

AB - The anthracyclines are commonly used for the treatment of early stage and advanced stage breast cancer, but many patients develop resistance to therapy. The definition of anthracycline resistance varies considerably in the literature, but in most cases includes disease progression during or within 6-12 months after completion of anthracycline therapy. Some authors have distinguished true anthracycline resistance (defined as progression during anthracycline therapy) from anthracycline pretreatment (defined as progression after completion of therapy). Single agents that have demonstrated response rates of at least 15-20% in anthracycline pretreated or resistant disease include the antitubulin agents (docetaxel, paclitaxel, vinorelbine), antimetabolites (capecitabine, fluorouracil), nucleoside analogues (gemcitabine), and trastuzumab (for HER2/neu positive disease only). Phase III studies have demonstrated that docetaxel is more effective than paclitaxel, mitomycin/vinblastine, and methotrexate/fluorouracil, and that the docetaxel/capecitabine combination is more effective than docetaxel alone. The decision regarding which agent(s) to use should be based upon the patient's prior treatment history, tumor biology (HER2/neu and hormone receptor expression), comorbid conditions (e.g. neuropathy, heart disease), and other considerations (e.g. insurance coverage for oral medication). The choice of a specific treatment regimen must be individualized based upon these considerations.

UR - http://www.scopus.com/inward/record.url?scp=4544341874&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4544341874&partnerID=8YFLogxK

U2 - 10.2165/00024669-200403030-00002

DO - 10.2165/00024669-200403030-00002

M3 - Article

VL - 3

SP - 151

EP - 162

JO - American Journal of Cancer

JF - American Journal of Cancer

SN - 1175-6357

IS - 3

ER -